Solventum Corporation
NYSE:SOLVMedical - Care Facilities
-$2.00 today
- Market cap
- $14.70B
- Beta
- 0.75
- P/E (TTM)
- 9.1
- EPS (TTM)
- $8.22
Volume 0.76M
Average 1.70M
SOLV Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Solventum CorporationNYSE: SOLV
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $178M fell 5.8% year over year, in line with the -5.7% change in trailing-twelve-month research & development. Sequentially, it fell 5.8% from the prior quarter. Over 3 fiscal years it compounded at -1.2% a year.
Context
- Research & development amounted to 8.9% of revenue in FY2025, down 0.5 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -5.8% toward the trailing-twelve-month pace of -5.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 739M USD
- Year-over-year change
- -4.6%
- 4-year CAGR
- -0.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 739M | -4.6% |
| FY2024 | 2024-12-31 | 775M | +2.2% |
| FY2023 | 2023-12-31 | 758M | -1.2% |
| FY2022 | 2022-12-31 | 767M | +0.1% |
| FY2021 | 2021-12-31 | 766M | — |
Research & Development vs competitors
How SOLV compares with its peers on the latest reported figures
- SOLV's LTM Jun 2026 research & development of $726M is the 2nd highest of the 10 companies compared; the peer median is $121.8M.
- Its year-over-year change of -5.7% is the 7th highest of 9, against a peer median of -1.6%.
- Research & development amounts to 8.7% of revenue for SOLV, versus a peer median of 4.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.07B | -15.3% | -7.2% | 5.3% | |
| LTM Jun 2026 | $726M | -5.7% | -1.2% | 8.7% | |
| LTM Jun 2026 | $512M | -16.6% | +4.8% | 4.5% | |
| LTM Jul 2026 | $169.8M | +0.8% | +16.0% | 4.0% | |
| LTM Mar 2026 | $158M | -0.6% | -4.8% | 4.3% | |
| LTM Oct 2026 | $121.8M | +12.2% | +4.4% | 4.2% | |
| LTM Sep 2026 | $96.93M | +1.0% | +8.8% | 6.0% | |
| LTM Jun 2026 | $86.32M | -2.5% | -2.0% | 4.0% | |
| LTM Mar 2026 | $668K | -5.0% | +10.7% | 1.8% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding SOLV) | $121.8M | -1.6% | +4.6% | 4.2% | |
Competitors are the stored peer set for SOLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8.17B | 8.13B | 8.2B | 8.25B | 8.33B |
| Cost of Revenue | 3.25B | 3.44B | 3.5B | 3.66B | 3.87B |
| Gross Profit | 4.92B | 4.7B | 4.69B | 4.59B | 4.45B |
| Gross Margin | 60.2% | 57.7% | 57.3% | 55.6% | 53.5% |
| Research & Development | 766M | 767M | 758M | 775M | 739M |
| Selling, General & Admin | 2.28B | 2.24B | 2.24B | 2.78B | 3.08B |
| Operating Expenses | 3.04B | 3B | 3B | 3.56B | 2.27B |
| Depreciation & Amortization | 597M | 578M | 561M | 555M | 489M |
| EBITDA | 2.48B | 2.27B | 2.23B | 1.53B | 2.55B |
| EBITDA Margin | 30.3% | 27.9% | 27.2% | 18.5% | 30.6% |
| Operating Income | 1.88B | 1.69B | 1.69B | 1.04B | 2.18B |
| Operating Margin | 23.0% | 20.8% | 20.6% | 12.6% | 26.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 367M | 347M |
| Other Income / Expenses | 3M | (1M) | (25M) | (431M) | (468M) |
| Income Before Tax | 1.88B | 1.69B | 1.67B | 605M | 1.71B |
| Pre-Tax Margin | 23.0% | 20.8% | 20.3% | 7.3% | 20.6% |
| Income Tax Expense | 422M | 349M | 321M | 127M | 157M |
| Net Income | 1.46B | 1.34B | 1.35B | 479M | 1.56B |
| Net Margin | 17.9% | 16.5% | 16.4% | 5.8% | 18.7% |
| EPS (Basic) | 8.47 | 7.79 | 7.79 | 2.77 | 8.94 |
| EPS (Diluted) | 8.47 | 7.79 | 7.79 | 2.76 | 8.88 |
| Weighted Avg Shares | 172.47M | 172.47M | 172.71M | 173.2M | 174.1M |
| Weighted Avg Shares (Diluted) | 172.47M | 172.47M | 172.71M | 173.7M | 175.3M |
Solventum Corporation
NYSE:SOLV
Intrinsic Alpha fair value
Locked
Current Price
$86.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.